Regenerative medicine in the treatment of gastro-esophageal reflux disease and laryngo-pharyngeal reflux. From research to cure.

Autor: Aragona SE; Regenerative Medicine Centre, Humanitas Mater Domini, Castellanza (VA), Italy., Mereghetti G; Regenerative Medicine Centre, Humanitas Mater Domini, Castellanza (VA), Italy., Bianchetti M; Gastroenterology Service, Humanitas Mater Domini, Castellanza (VA), Italy., Mangiavillano B; Gastroenterology Service, Humanitas Mater Domini, Castellanza (VA), Italy., Zurlo T; Otolaringology Service, Humanitas Mater Domini, Castellanza (VA), Italy., Lotti J; Department of Nuclear, Subnuclear, and Radiation Physics, University of Rome “G. Marconi”, Rome, Italy., La Mantia I; UOC Otolaringology, University of Catania, Catania, Italy., França K; Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami Miller School of Medicine, Miami, FL, USA., Lotti T; Chair of Dermatology, CSRMR, University of Rome “G. Marconi”, Rome, Italy.
Jazyk: angličtina
Zdroj: Journal of biological regulators and homeostatic agents [J Biol Regul Homeost Agents] 2017 APR-JUN; Vol. 31 (2 Suppl. 2), pp. 207-212.
Abstrakt: We present our observational study on 40 patients treated with the medical device containing sodium hyaluronic acid and magnesium alginate, performing a lubricating and hydrating action. This device is in the form of a gel, with topical action to contrast gastroesophageal reflux and to exert a mechanical role of protection of the mucosal tissues (mouth-pharyngo-esophageal mucosa and gastric mucose.). Forty patients were recruited aged between 22- and 72-years-old with painful dyspeptic Gastro Esophageal Reflux Disease (GERD) symptomatology in acute or in clinical phase (25 patients) and with pharyngolaryngo- tracheal symptomatology (15 patients). Patients were divided into two clinical groups: Group A was treated with the medical device, while Group B with conventional treatments without the medical device. Subjects of both groups were also treated with proton pump inhibitors (PPIs). Follow-up was at 10, 20 and 30 days and patients were evaluated for reduction of their subjective symptoms, reduction of symptomatic and occasional therapies, reduction of inflammatory process or disappearance of epithelial lesions of the examined mucosa, healing process. The reduction of subjective symptoms was observed at 10 days in the patient with food bolus (disappearance after 5 days) and in patients with a reduction of 70%. A relevant reduction in the use of symptomatic drugs was noted. Our data are relevant considering symptom relief (heartburn, reflux and dyspepsia). New scenarios for the treatment of inflammatory diseases of the digestive and respiratory tract mucosa are at the horizon. Interdisciplinary translational research brings to the development of novel medical devices (as the one described in this study) with a high safety profile, and extremely active on the inflammation-repair-regeneration complex of different tissues and organs.
Databáze: MEDLINE